Skip to main content
ADVANCED SEARCH
Log in
Top
Archives of Dermatological Research
Published in:

Open Access 01-08-2024 | SARS-CoV-2 | REVIEW

The most common skin symptoms in young adults and adults related to SARS-CoV-2 virus infection

Authors: Monika Zaborska, Maksymilan Chruszcz, Jakub Sadowski, Tomasz Klaudel, Michał Pelczarski, Anna Sztangreciak-Lehun, Rafał Jakub Bułdak

Published in: Archives of Dermatological Research | Issue 6/2024

Login to get access

Abstract

Scientists from various areas of the world indicate in their studies that skin lesions occur in the course of infection with the SARS-CoV-2 virus. This article is a review of the most frequently described cutaneous manifestations of SARS-CoV-2 virus infection and the potential pathophysiology of their development, as well as information on abnormalities in histopathological tests. The article describes the impact of some factors related to the COVID-19 pandemic on the exacerbation of chronic dermatological diseases. This work was constructed on the basis of 142 research studies, reviews, and meta-analyses, focusing on the methods and materials used in individual works as well as the results and conclusions resulting from them. Some skin lesions may be a potential prognostic marker of the course of the disease and may also be a prodromal symptom or the only symptom of SARS-CoV-2 virus infection. Stress related to the COVID-19 pandemic may exacerbate some chronic dermatological diseases. A correlation was observed between the type of skin lesions and the patient’s age. The occurrence of skin diseases may also be influenced by drugs used to treat infections caused by SARS-CoV-2. A relationship was observed between the patient’s ethnic origin and skin lesions occurring in the course of COVID-19. There is a need to further diagnose the cutaneous manifestations of SARS-CoV-2 infection and to learn the detailed pathomechanism of their occurrence in order to better understand the essence of the disease and find an appropriate treatment method.
Literature
1.
Afrisham R, Jadidi Y, Davoudi M, Moayedi K, Karami S, Sadegh-Nejadi S et al (2022) Renal, cardiac, neurological, cutaneous and coagulopathic long-term manifestations of COVID-19 after recovery. A review Epidemiol Infect 150:e208PubMed
2.
Sohrabi C, Mathew G, Franchi T, Kerwan A, Griffin M, Del SolleliMundo SCJ et al (2021) Impact of the coronavirus (COVID-19) pandemic on scientific research and implications for clinical academic training – A review. Int J Surg 86:57–63PubMedPubMedCentral
3.
Das S, Samanta S, Banerjee J, Pal A, Giri B, Kar SS et al (2022) Is Omicron the end of pandemic or start of a new innings? Travel Med Infect Dis 48:102332PubMedPubMedCentral
4.
5.
6.
Parums DV (2023) Editorial: factors driving new variants of SARS-CoV-2, immune escape, and resistance to antiviral treatments as the end of the COVID-19 pandemic is declared. Med Sci Monit 29:e942960PubMedPubMedCentral
7.
8.
Stobnicka A, Górny J (2020) Koronawirusy – niewidzialne zagrożenie o globalnym zasięgu. Podstawy i Metody Oceny Środowiska Pracy 36:5–35
9.
Zoumpourlis V, Goulielmaki M, Rizos E, Baliou S, Spandidos D (2020) [Comment] The COVID-19 pandemic as a scientific and social challenge in the 21st century. Mol Med Rep 22(4):3035–3048PubMedPubMedCentral
10.
Hu B, Guo H, Zhou P, Shi Z-L (2021) Characteristics of SARS-CoV-2 and COVID-19. Nat Rev Microbiol 19:141–154PubMed
11.
Mousavizadeh L, Ghasemi S (2021) Genotype and phenotype of COVID-19: Their roles in pathogenesis. J Microbiol Immunol Infect 54:159–163PubMed
12.
Davis HE, McCorkell L, Vogel JM, Topol EJ (2023) Long COVID: major findings, mechanisms and recommendations. Nat Rev Microbiol 21:133–146PubMedPubMedCentral
13.
Guan W, Ni Z, Hu Y, Liang W, Ou C, He J et al (2020) Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med 382:1708–1720PubMed
14.
Tamai M, Sakamoto R, Goto N, Morimura O, Nishida T, Iwahashi H et al (2022) Cutaneous manifestations of coronavirus disease 2019 patients in Japan. J Dermatol 49:872–878PubMedPubMedCentral
15.
Punyaratabandhu P, Chirachanakul P (2021) Cutaneous eruption in COVID-19-infected patients in Thailand: An observational descriptive study. J Dermatol 48:14–20PubMed
16.
Pangti R, Gupta S, Nischal N, Trikha A (2021) Recognizable vascular skin manifestations of SARS-CoV-2 (COVID-19) infection are uncommon in patients with darker skin phototypes. Clin Exp Dermatol 46:180–182PubMedPubMedCentral
17.
Seque CA, Enokihara MMSES, Porro AM, Tomimori J (2022) Skin manifestations associated with COVID-19. An Bras Dermatol 97(1):75–88PubMed
18.
Nakashima C, Kato M, Otsuka A (2023) Cutaneous manifestations of COVID-19 and COVID-19 vaccination. J Dermatol 50:280–289PubMed
19.
Hoffmann M, Kleine-Weber H, Schroeder S, Krüger N, Herrler T, Erichsen S et al (2020) SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. Cell 181:271–280PubMedPubMedCentral
20.
Haq IU, Krukiewicz K, Tayyab H, Khan I, Khan M, Yahya G et al (2023) Molecular understanding of ACE-2 and HLA-conferred differential susceptibility to COVID-19: host-directed insights opening new windows in COVID-19 therapeutics. J Clin Med 12:2645PubMedPubMedCentral
21.
Wollina U, Karadağ AS, Rowland-Payne C, Chiriac A, Lotti T (2020) Cutaneous signs in COVID-19 patients: a review. Dermatol Ther 33(5):13549
22.
Parasher A (2021) COVID-19: current understanding of its pathophysiology, clinical presentation and treatment. Postgrad Med J 97:312–320PubMed
23.
Sridhar S, Nicholls J (2021) Pathophysiology of infection with SARS-CoV-2— What is known and what remains a mystery. Respirology 26:652–665PubMedPubMedCentral
24.
Lamers MM, Haagmans BL (2022) SARS-CoV-2 pathogenesis. Nat Rev Microbiol 20:270–284PubMed
25.
Trougakos IP, Stamatelopoulos K, Terpos E, Tsitsilonis OE, Aivalioti E, Paraskevis D et al (2021) Insights to SARS-CoV-2 life cycle, pathophysiology, and rationalized treatments that target COVID-19 clinical complications. J Biomed Sci 28:9PubMedPubMedCentral
26.
Scialo F, Daniele A, Amato F, Pastore L, Matera MG, Cazzola M et al (2020) ACE2: the major cell entry receptor for SARS-CoV-2. Lung 198:867–877PubMedPubMedCentral
27.
Shirbhate E, Pandey J, Patel VK, Kamal M, Jawaid T, Gorain B et al (2021) Understanding the role of ACE-2 receptor in pathogenesis of COVID-19 disease: a potential approach for therapeutic intervention. Pharmacol Rep 73:1539–1550PubMedPubMedCentral
28.
Jahanafrooz Z, Chen Z, Bao J, Li H, Lipworth L, Guo X (2022) An overview of human proteins and genes involved in SARS-CoV-2 infection. Gene 808:145963PubMed
29.
Dong M, Zhang J, Ma X, Tan J, Chen L, Liu S et al (2020) ACE2, TMPRSS2 distribution and extrapulmonary organ injury in patients with COVID-19. Biomed Pharmacother 131:110678PubMedPubMedCentral
30.
Magro C, Nuovo G, Mulvey JJ, Laurence J, Harp J, Crowson AN (2021) The skin as a critical window in unveiling the pathophysiologic principles of COVID-19. Clin Dermatol 39:934–965PubMedPubMedCentral
31.
32.
Ricardo Criado P, Pincelli TPH, Criado RFJ, Abdalla BMZ, Belda JW (2020) Potential interactions of SARS-CoV-2 with human cell receptors in the skin: understanding the enigma for a lower frequency of skin lesions compared to other tissues. Exp Dermatol 29:936–944PubMed
33.
Urticaria. Interdisciplinary diagnostic and therapeutic recommendations of the Polish Dermatological Society and the Polish Society of Allergology. Dermatology Review. 2020;107:1–14.
34.
Tan SW, Tam YC, Oh CC (2021) Skin manifestations of COVID-19: a worldwide review. JAAD Int 2:119–133PubMed
35.
Freeman EE, Chamberlin GC, McMahon DE, Hruza GJ, Wall D, Meah N et al (2021) Dermatology COVID-19 Registries. Dermatol Clin 39:575–585PubMedPubMedCentral
36.
Galván Casas C, Català A, Carretero Hernández G, Rodríguez-Jiménez P, Fernández-Nieto D, Rodríguez-Villa Lario A et al (2020) Classification of the cutaneous manifestations of COVID-19: a rapid prospective nationwide consensus study in Spain with 375 cases. Br J Dermatol 183:71–77PubMedPubMedCentral
37.
Dalal A, Jakhar D, Agarwal V, Beniwal R (2020) Dermatological findings in SARS-CoV-2 positive patients: An observational study from North India. Dermatol Ther 33(6):e13849PubMedPubMedCentral
38.
de Masson A, Bouaziz J-D, Sulimovic L, Cassius C, Jachiet M, Ionescu M-A et al (2020) Chilblains is a common cutaneous finding during the COVID-19 pandemic: a retrospective nationwide study from France. J Am Acad Dermatol 83:667–670PubMedPubMedCentral
39.
Askin O, Altunkalem RN, Altinisik DD, Uzuncakmak TK, Tursen U, Kutlubay Z (2020) Cutaneous manifestations in hospitalized patients diagnosed as COVID-19. Dermatol Ther 33(6):e13896PubMedPubMedCentral
40.
Najafzadeh M, Shahzad F, Ghaderi N, Ansari K, Jacob B, Wright A (2020) Urticaria (angioedema) and COVID-19 infection. J Eur Acad Dermatolo and Venereolo 34(10):e568–e670
41.
Hassan K (2020) Urticaria and angioedema as a prodromal cutaneous manifestation of SARS-CoV-2 (COVID-19) infection. BMJ Case Rep 13:e236981PubMedPubMedCentral
42.
Kaushik A, Parsad D, Kumaran MS (2020) Urticaria in the times of COVID-19. Dermatol Ther 33(6):13817
43.
Pathania YS (2022) Urticaria and COVID-19 infection: a critical appraisal. J Dermatol Treat 33:1777–1777
44.
Türsen Ü, Türsen B, Lotti T (2020) Cutaneous sıde-effects of the potential COVID-19 drugs. Dermatol Ther 33(4):e13476PubMedPubMedCentral
45.
Pendlebury GA, Oro P, Haynes W, Merideth D, Bartling S, Bongiorno MA (2022) The Impact of COVID-19 pandemic on dermatological conditions: a novel. Comprehensive Review Dermatopathology 9:212–243PubMed
46.
Marzano AV, Genovese G, Moltrasio C, Gaspari V, Vezzoli P, Maione V et al (2021) The clinical spectrum of COVID-19–associated cutaneous manifestations: an Italian multicenter study of 200 adult patients. J Am Acad Dermatol 84:1356–1363PubMedPubMedCentral
47.
Garcia-Lara G, Linares-González L, Ródenas-Herranz T, Ruiz-Villaverde R (2020) Chilblain-like lesions in pediatrics dermatological outpatients during the COVID-19 outbreak. Dermatol Ther 33(5):e13516PubMedPubMedCentral
48.
Piccolo V, Neri I, Filippeschi C, Oranges T, Argenziano G, Battarra VC et al (2020) Chilblain-like lesions during COVID-19 epidemic: a preliminary study on 63 patients. J Eur Acad Dermatol Venereol 34(7):e291–e293PubMedPubMedCentral
49.
Bouaziz JD, Duong TA, Jachiet M, Velter C, Lestang P, Cassius C et al (2020) Vascular skin symptoms in COVID-19: a French observational study. J Eur Acad Dermatolo Venereolo 34(9):e451–e452
50.
Andina D, Noguera-Morel L, Bascuas-Arribas M, Gaitero-Tristán J, Alonso-Cadenas JA, Escalada-Pellitero S et al (2020) Chilblains in children in the setting of COVID-19 pandemic. Pediatr Dermatol 37:406–411PubMedPubMedCentral
51.
Martora F, Villani A, Fabbrocini G, Battista T (2023) COVID-19 and cutaneous manifestations: a review of the published literature. J Cosmet Dermatol 22:4–10PubMed
52.
Cappel JA, Wetter DA (2014) Clinical Characteristics, Etiologic Associations, Laboratory Findings, Treatment, and Proposal of Diagnostic Criteria of Pernio (Chilblains) in a Series of 104 Patients at Mayo Clinic, 2000 to 2011. Mayo Clin Proc 89:207–215PubMed
53.
Maiti AK (2020) The African-American population with a low allele frequency of SNP rs1990760 (T allele) in IFIH1 predicts less IFN-beta expression and potential vulnerability to COVID-19 infection. Immunogenetics 72:387–391PubMedPubMedCentral
54.
Carrascosa JM, Morillas V, Bielsa I, Munera-Campos M (2020) Manifestaciones cutáneas en el contexto de la infección por SARS-CoV-2 (COVID-19). Actas Dermosifiliogr 111:734–742PubMedPubMedCentral
55.
El Hachem M, Diociaiuti A, Concato C, Carsetti R, Carnevale C, Ciofi Degli AM et al (2020) A clinical, histopathological and laboratory study of 19 consecutive Italian paediatric patients with chilblain-like lesions: lights and shadows on the relationship with COVID-19 infection. J Eur Acad Dermatol Venereol 34:2620–2629PubMedPubMedCentral
56.
Arefinia N, Ghoreshi ZA, Alipour AH, Iranmanesh B, Mehrolhasani N, Shamsi-Meymandi S, Sarvari J (2023) A comprehensive narrative review of the cutaneous manifestations associated with COVID-19. Int Wound J 20(3):871–879PubMed
57.
Tatka A, Pawliczak R (2022) Skin manifestations associated with COVID-19. Alergologia Polska - Polish Journal of Allergology. 9:143–149
58.
Avellana Moreno R, Estela Villa LM, Avellana Moreno V, Estela Villa C, Moreno Aparicio MA, Avellana Fontanella JA (2020) Cutaneous manifestation of COVID-19 in images: a case report. J Eur Acad Dermatol Venereol 34(7):e307–e309PubMedPubMedCentral
59.
Herrero-Moyano M, Capusan TM, Andreu-Barasoain M, Alcántara-González J, Ruano-Del Salado M, Sánchez-Largo Uceda ME et al (2020) A clinicopathological study of eight patients with COVID-19 pneumonia and a late-onset exanthema. J Eur Acad Dermatol Venereol 34(9):e460–e464PubMedPubMedCentral
60.
Reymundo A, Fernáldez-Bernáldez A, Reolid A, Butrón B, Fernández-Rico P, Muñoz-Hernández P, Clinical and histological characterization of late appearance maculopapular eruptions in association with the coronavirus disease, et al (2019) A case series of seven patients. J Eur Acad Dermatol Venereol 2020:34
61.
Zengarini C, Orioni G, Cascavilla A, Horna Solera C, Fulgaro C, Misciali C et al (2020) Histological pattern in COVID-19-induced viral rash. J Eur Acad Dermatol Venereol 34(9):e453–e454PubMedPubMedCentral
62.
Rubio-Muniz CA, Puerta-Peña M, Falkenhain-López D, Arroyo-Andrés J, Agud-Dios M, Rodriguez-Peralto JL et al (2020) The broad spectrum of dermatological manifestations in COVID-19: clinical and histopathological features learned from a series of 34 cases. J Eur Acad Dermatol Venereol 34(10):e574–e576PubMedPubMedCentral
63.
64.
Daneshgaran G, Dubin DP, Gould DJ (2020) Cutaneous Manifestations of COVID-19: An Evidence-Based Review. Am J Clin Dermatol 21:627–639PubMedPubMedCentral
65.
Marzano AV, Genovese G, Fabbrocini G, Pigatto P, Monfrecola G, Piraccini BM et al (2020) Varicella-like exanthem as a specific COVID-19–associated skin manifestation: Multicenter case series of 22 patients. J Am Acad Dermatol 83:280–285PubMedPubMedCentral
66.
Freeman EE, McMahon DE, Lipoff JB, Rosenbach M, Kovarik C, Desai SR et al (2020) The spectrum of COVID-19–associated dermatologic manifestations: An international registry of 716 patients from 31 countries. J Am Acad Dermatol 83:1118–1129PubMedPubMedCentral
67.
Fernandez-Nieto D, Ortega-Quijano D, Jimenez-Cauhe J, Burgos-Blasco P, Perosanz-Lobo D, Suarez-Valle A et al (2020) Clinical and histological characterization of vesicular COVID-19 rashes: a prospective study in a tertiary care hospital. Clin Exp Dermatol 45:872–875PubMedPubMedCentral
68.
69.
Criado PR, Abdalla BMZ, de Assis IC, van Blarcum C, Caputo GC, Vieira IC (2020) Are the cutaneous manifestations during or due to SARS-CoV-2 infection/COVID-19 frequent or not? Revision of possible pathophysiologic mechanisms. Inflamm Res 69:745–756PubMedPubMedCentral
70.
Genovese G, Moltrasio C, Berti E, Marzano AV (2021) Skin Manifestations associated with COVID-19: current knowledge and future perspectives. Dermatology 237:1–12PubMed
71.
72.
Bennardo L, Nisticò SP, Dastoli S, Provenzano E, Napolitano M, Silvestri M et al (2021) Erythema Multiforme and COVID-19: What Do We Know? Medicina (B Aires). 57:828
73.
Soares A, Sokumbi O (2021) Recent Updates in the Treatment of Erythema Multiforme. Medicina (B Aires). 57:921
74.
Sajjan V, Lunge S, Swamy M, Pandit A (2015) Livedo reticularis: A review of the literature. Indian Dermatol Online J 6:315PubMedPubMedCentral
75.
Tang N, Li D, Wang X, Sun Z (2020) Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia. J Thromb Haemost 18:844–847PubMedPubMedCentral
76.
Chand S, Rrapi R, Lo JA, Song S, Gabel CK, Desai N et al (2021) Purpuric ulcers associated with COVID-19: A case series. JAAD Case Rep. 11:13–19PubMedPubMedCentral
77.
Manalo IF, Smith MK, Cheeley J, Jacobs R (2020) Reply to: “Reply: A dermatologic manifestation of COVID-19: Transient livedo reticularis.” J Am Acad Dermatol 83:e157PubMedPubMedCentral
78.
Bosch-Amate X, Giavedoni P, Podlipnik S, Andreu-Febrer C, Sanz-Beltran J, Garcia-Herrera A et al (2019) Retiform purpura as a dermatological sign of coronavirus disease (COVID-19) coagulopathy. J Eur Acad Dermatol Venereol 2020:34
79.
Öncü INS, Güler D, Gürel G, Yalçın GŞ (2021) Pityriasis Rosea in a Confirmed COVID-19 Pediatric Patient. Actas Dermo-Sifiliográficas (English Edition). 112:864–865
80.
Birlutiu V, Birlutiu RM, Iancu GM (2021) Pityriasis rosea Gibert triggered by SARS-CoV-2 infection. Medicine 100:e25352PubMedPubMedCentral
81.
Leung AKC, Lam JM, Leong KF, Hon KL (2021) Pityriasis Rosea: An Updated Review. Curr Pediatr Rev 17:201–211PubMed
82.
83.
84.
Ciccarese G, Drago F, Marinaro E, Parodi A (2022) Pityriasis rosea during COVID-19: Pathogenesis, diagnosis, and treatment. J Med Virol 94:2915–2916PubMedPubMedCentral
85.
86.
87.
Kim DH, Cho JH, Park SJ, Seo SH, Ahn HH (2022) Impact of COVID-19 on Clinicopathological spectrum of pityriasis rosea in Korea. J Korean Med Sci 37(24):e190PubMedPubMedCentral
88.
Wasuwanich P, So JM, Chakrala TS, Chen J, Motaparthi K (2023) Epidemiology of Stevens-Johnson syndrome and toxic epidermal necrolysis in the United States and factors predictive of outcome. JAAD Int. 13:17–25PubMedPubMedCentral
89.
90.
Miller AE, Zhang D, Shields BE, Borghesi A, Benincaso AR, Bernardo L et al (2023) COVID-19 associated severe mucocutaneous blistering eruptions: a case series. Pediatr Dermatol 40:990–995PubMed
91.
Khade P, Shah A, Kharkar V (2023) Stevens-Johnson Syndrome in Adult Patient Secondary to COVID-19 Infection: Case Report. JMIR Dermatol. 6:e45062PubMedPubMedCentral
92.
Henderson LA, Canna SW, Friedman KG, Gorelik M, Lapidus SK, Bassiri H, Behrens EM, Kernan KF, Schulert GS, Seo P, Son MBF, Tremoulet AH, VanderPluym C, Yeung RSM, Mudano AS, Turner AS, Karp DR, Mehta JJ (2022) American College of Rheumatology Clinical Guidance for Multisystem Inflammatory Syndrome in Children Associated With SARS-CoV-2 and Hyperinflammation in Pediatric COVID-19: Version 3. Arthritis Rheumatol 74(4):e1–e20. https://​doi.​org/​10.​1002/​art.​42062CrossRefPubMedPubMedCentral
93.
Waseem M, Shariff MA, Tay ET, Mortel D, Savadkar S, Lee H et al (2022) Multisystem Inflammatory Syndrome in Children. J Emerg Med 62:28–37PubMed
94.
Hennon TR, Yu KOA, Penque MD, Abdul-Aziz R, Chang AC, McGreevy MB et al (2021) COVID-19 associated Multisystem Inflammatory Syndrome in Children (MIS-C) guidelines; revisiting the Western New York approach as the pandemic evolves. Prog Pediatr Cardiol 62:101407PubMedPubMedCentral
95.
96.
Radia T, Williams N, Agrawal P, Harman K, Weale J, Cook J et al (2021) Multi-system inflammatory syndrome in children & ; adolescents (MIS-C): A systematic review of clinical features and presentation. Paediatr Respir Rev 38:51–57PubMed
97.
Matic KM (2021) SARS-CoV-2 and Multisystem Inflammatory Syndrome In Children (MIS-C). Curr Probl Pediatr Adolesc Health Care 51:101000PubMedPubMedCentral
98.
Kim MM, Murthy S, Goldman RD (2021) Post–COVID-19 multisystem inflammatory syndrome in children. Can Fam Physician 67:594–596PubMedPubMedCentral
99.
Sharma C, Ganigara M, Galeotti C, Burns J, Berganza FM, Hayes DA et al (2021) Multisystem inflammatory syndrome in children and Kawasaki disease: a critical comparison. Nat Rev Rheumatol 17:731–748PubMedPubMedCentral
100.
101.
Brumfiel CM, DiLorenzo AM, Petronic-Rosic VM (2021) Dermatologic manifestations of COVID-19-associated multisystem inflammatory syndrome in children. Clin Dermatol 39:329–333PubMed
102.
Böncüoğlu E, Kıymet E, Şahinkaya Ş, Cem E, Yılmaz Çelebi M, Düzgöl M et al (2021) Mucocutaneous findings of multisystem inflammatory syndrome in children: a single-center experience. J Trop Pediatr 67(3):070
103.
Young TK, Shaw KS, Shah JK, Noor A, Alperin RA, Ratner AJ et al (2021) Mucocutaneous manifestations of multisystem inflammatory syndrome in children during the COVID-19 pandemic. JAMA Dermatol 157:207PubMed
104.
Grover C, Saha S, Pandhi D (2022) Nail changes in COVID-19: A cross sectional study from India. Indian Dermatol Online J 13:326PubMedPubMedCentral
105.
Sil A, Ghosh S, Das A, Chandra A (2022) Transverse erythronychia: A unique nail manifestation of COVID-19 infection and brief review of COVID-19 associated nail changes. Journal of the Royal College of Physicians of Edinburgh 52:320–323PubMed
106.
Ivanova ZG, Aleksiev TI, Dobrev HP (2023) Onychomadesis in a COVID-19 patient. Wien Med Wochenschr 173:272–275PubMed
107.
Preda-Naumescu A, Penney K, Pearlman RL, Brodell RT, Daniel CR, Nahar VK (2021) Nail Manifestations in COVID-19: Insight into a Systemic Viral Disease. Skin Appendage Disord. 7:433–438PubMedCentral
108.
Ocampo-Garza SS, Ocampo-Candiani J, Camela E, Vastarella M, Fabbrocini G, Scalvenzi M et al (2021) Nail changes as manifestation of systemic disease in COVID-19 infection. J Eur Acad Dermatol Venereol 35(8):e474PubMedPubMedCentral
109.
110.
Fernandez-Nieto D, Jimenez-Cauhe J, Ortega-Quijano D, Diaz-Guimaraens B, Dominguez-Santas M, Martinez-Rubio J (2020) Transverse leukonychia (Mees’ lines) nail alterations in a COVID -19 patient. Dermatol Ther 33(6):e13863PubMedPubMedCentral
111.
Kim BR, Yu D-A, Lee SR, Lim SS, Mun J-H (2023) Beau’s Lines and Onychomadesis: a systematic review of characteristics and aetiology. Acta Derm Venereol 103:18251PubMedPubMedCentral
112.
Alobaida S, Lam JM (2020) Beau lines associated with COVID-19. Can Med Assoc J 192:E1040
113.
Deng J, Ngo T, Zhu TH, Halverstam C (2021) Telogen effluvium, Beau lines, and acral peeling associated with COVID-19 infection. JAAD Case Rep. 13:138–140PubMedPubMedCentral
114.
Chodkiewicz J, Gola M (2021) Fear of COVID-19 and death anxiety: Polish adaptations of scales. Postępy Psychiatrii i Neurologii. 30:61–72PubMedPubMedCentral
115.
Ide S, Morioka S, Inada M, Ohmagari N (2020) Beau’s Lines and Leukonychia in a COVID-19 Patient. Intern Med 59:3259–3259PubMedPubMedCentral
116.
Ferreira BR, Jafferany M, Misery L (2021) Psychodermatology in the Era of COVID-19. J Clin Aesthet Dermatol. 14:S24–S27PubMedPubMedCentral
117.
118.
119.
Meng Y, Zeng F, Sun H, Li Y, Chen X, Deng G (2022) Clinical characteristics and outcomes of patients with COVID-19 and psoriasis. J Med Virol 94:5850–5857PubMed
120.
Griffiths CEM, Armstrong AW, Gudjonsson JE, Barker JNWN (2021) Psoriasis. The Lancet 397:1301–1315
121.
Raharja A, Mahil SK, Barker JN (2021) Psoriasis: a brief overview. Clin Med 21:170–173
122.
Hölsken S, Krefting F, Schedlowski M, Sondermann W (2021) Common fundamentals of psoriasis and depression. Acta Derm Venereol 101:00609
123.
Petit RG, Cano A, Ortiz A, Espina M, Prat J, Muñoz M et al (2021) Psoriasis: from pathogenesis to pharmacological and nano-technological-based therapeutics. Int J Mol Sci 22:4983PubMedPubMedCentral
124.
Elmas ÖF, Demirbaş A, Kutlu Ö, Bağcıer F, Metin MS, Özyurt K et al (2020) Psoriasis and COVID-19: A narrative review with treatment considerations. Dermatol Ther 33(6):e13858PubMedPubMedCentral
125.
126.
Mahil SK, Dand N, Mason KJ, Yiu ZZN, Tsakok T, Meynell F et al (2021) Factors associated with adverse COVID-19 outcomes in patients with psoriasis—insights from a global registry–based study. Journal of Allergy and Clinical Immunology 147:60–71PubMed
127.
Frazier W, Bhardwaj N (2020) Atopic dermatitis: diagnosis and treatment. Am Fam Physician 101:590–598PubMed
128.
129.
Chen W-Y, Chen S-C, Hsu S-Y, Lin Y-A, Shih C-M, Huang C-Y et al (2022) Annoying psoriasis and atopic dermatitis: a narrative review. Int J Mol Sci 23:4898PubMedPubMedCentral
130.
Patruno C, Nisticò SP, Fabbrocini G, Napolitano M (2020) COVID-19, quarantine, and atopic dermatitis. Med Hypotheses 143:109852PubMedPubMedCentral
131.
Hernández N, Sanclemente G, Tamayo L, López Á, Seidel A, Hernandez N et al (2021) Atopic dermatitis in the COVID-19 era: Results from a web-based survey. World Allergy Organ J 14:100571PubMedPubMedCentral
132.
Harmouche M, Kaplan M, Weisshaar E (2023) Wenn Schutzhandschuhe nicht schützen – Unerwartetes bei einer Zahnmedizinischen Fachangestellten. Die Dermatologie. 74:448–452PubMed
133.
Mirali S, Fleming P, Lynde CW (2021) Moisturizers and cleansers in the management of skin conditions caused by personal protective equipment and frequent handwashing. Skin Therapy Lett. 26:9–13PubMed
134.
Fan R, Leasure AC, Damsky W, Cohen JM (2022) Association between atopic dermatitis and COVID-19 infection: A case-control study in the All of Us research program. JAAD Int. 6:77–81PubMed
135.
Chiricozzi A, Talamonti M, De Simone C, Galluzzo M, Gori N, Fabbrocini G et al (2021) Management of patients with atopic dermatitis undergoing systemic therapy during COVID-19 pandemic in Italy: Data from the DA-COVID-19 registry. Allergy 76:1813–1824PubMed
136.
137.
Di Mascio D, Sapino G, De Maria F (2021) Telogen Effluvium as a complication of scalp reconstruction with tissue expander: a case report. Acta Biomed 92:e2021431PubMedPubMedCentral
138.
Ocampo-Garza SS, Vastarella M, Nappa P, Cantelli M, Fabbrocini G (2021) Telogen effluvium in the new SARS-CoV-2 era. Int J Dermatol 60(9):e265PubMedPubMedCentral
139.
Abrantes TF, Artounian KA, Falsey R, Simão JCL, Vañó-Galván S, Ferreira SB et al (2021) Time of onset and duration of post-COVID-19 acute telogen effluvium. J Am Acad Dermatol 85:975–976PubMedPubMedCentral
140.
Aldahish A, Vasudevan R, Salem H, Alqahtani A, AlQasim S, Alqhatani A et al (2023) Telogen effluvium and COVID-19: a cross-sectional study. Eur Rev Med Pharmacol Sci 27:7823–7830PubMed
141.
Nguyen B, Tosti A (2022) Alopecia in patients with COVID-19: A systematic review and meta-analysis. JAAD Int. 7:67–77PubMedPubMedCentral
142.
Starace M, Iorizzo M, Sechi A, Alessandrini AM, Carpanese M, Bruni F et al (2021) Trichodynia and telogen effluvium in COVID-19 patients: Results of an international expert opinion survey on diagnosis and management. JAAD Int. 5:11–18PubMedPubMedCentral
Metadata
Title
The most common skin symptoms in young adults and adults related to SARS-CoV-2 virus infection
Authors
Monika Zaborska
Maksymilan Chruszcz
Jakub Sadowski
Tomasz Klaudel
Michał Pelczarski
Anna Sztangreciak-Lehun
Rafał Jakub Bułdak
Publication date
01-08-2024
Publisher
Springer Berlin Heidelberg
Published in
Archives of Dermatological Research / Issue 6/2024
Print ISSN: 0340-3696
Electronic ISSN: 1432-069X
DOI
https://doi.org/10.1007/s00403-024-02991-5

Other articles of this Issue 6/2024

Split-scalp pilot study to evaluate effectiveness of Minoxidil 0,5% MMP® versus Topical Minoxidil 5% in the treatment of Female Pattern Hair Loss

miR-181a/b-5p negatively regulates keratinocytes proliferation by targeting MELK

Steeper incidence rate and advanced staging of Merkel cell carcinoma in black patients

Based on scRNA-seq and bulk RNA-seq to establish tumor immune microenvironment-associated signature of skin melanoma and predict immunotherapy response

Patient preferences for educational materials in a tertiary care center’s oncodermatology clinic

  • RESEARCH LETTER

Clinic and dermoscopy of genital basal cell carcinomas (gBCCs): a retrospective analysis among 169 patients referred with genital skin neoplasms